

# Arndt Weinmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7754542/publications.pdf>

Version: 2024-02-01

122  
papers

4,579  
citations

117625

34  
h-index

118850

62  
g-index

123  
all docs

123  
docs citations

123  
times ranked

6159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
2	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells. <i>Hepatology Communications</i> , 2022, 6, 1140-1156.	4.3	6
3	Transforming Growth Factor- $\beta$ 2 Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. <i>Cancers</i> , 2022, 14, 430.	3.7	8
4	Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. <i>Liver Cancer</i> , 2022, 11, 219-232.	7.7	20
5	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. <i>JHEP Reports</i> , 2022, 4, 100417.	4.9	6
6	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>United European Gastroenterology Journal</i> , 2022, 10, 41-53.	3.8	12
7	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	3.2	43
8	Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. <i>European Radiology</i> , 2022, 32, 6302-6313.	4.5	13
9	Comprehensive clinicopathologic study of alpha fetoprotein expression in a large cohort of patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2022, 150, 1053-1066.	5.1	19
10	Liver transplantation and BCLC classification: Limitations impede optimum treatment. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 6-12.	1.3	6
11	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 388-397.	3.8	4
12	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
13	No Evidence for Classic Thrombotic Microangiopathy in COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 671.	2.4	9
14	Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 744.	3.7	28
15	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
16	The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis. <i>Autoimmunity Reviews</i> , 2021, 20, 102802.	5.8	4
17	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 403-419.	3.7	25
18	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0249426.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. <i>Journal of Clinical Medicine</i> , 2021, 10, 2071.	2.4	5
20	Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2426.	2.4	6
21	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. <i>Frontiers in Oncology</i> , 2021, 11, 696183.	2.8	17
22	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. <i>United European Gastroenterology Journal</i> , 2021, 9, 590-597.	3.8	9
23	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2732.	2.4	8
24	Nonbacterial thrombotic endocarditis in a patient with pancreatic carcinoma. <i>Echocardiography</i> , 2021, 38, 1455-1458.	0.9	1
25	Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. <i>BMC Health Services Research</i> , 2021, 21, 846.	2.2	2
26	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. <i>Cancers</i> , 2021, 13, 3961.	3.7	7
27	Liver Resection for Intrahepatic Cholangiocarcinoma—Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. <i>Journal of Clinical Medicine</i> , 2021, 10, 3559.	2.4	7
28	CXCR4 and hif-1 $\alpha$ as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. <i>Acta Oncologica</i> , 2021, 60, 1543-1547.	1.8	1
29	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
30	A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3309-3319.	2.4	1
31	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. <i>Cancers</i> , 2021, 13, 5018.	3.7	16
32	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	4.4	167
33	Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 626-634.	1.6	28
34	Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	4
35	Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	11
36	Investigating the impact of extrahepatic metastasis in patients with HCC: does location matter?. <i>Journal of Hepatology</i> , 2020, 73, S370-S371.	3.7	0

#	ARTICLE	IF	CITATIONS
37	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1883-1890.	2.5	9
38	Patterns of liver injury in COVID-19 – a German case series. <i>United European Gastroenterology Journal</i> , 2020, 8, 814-819.	3.8	23
39	Clinical Frailty Scale for Risk Stratification in Patients with Sars-Cov-2 Infection. <i>Journal of Investigative Medicine</i> , 2020, 68, 1199-1202.	1.6	32
40	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. <i>United European Gastroenterology Journal</i> , 2020, 8, 444-452.	3.8	9
41	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. <i>Liver International</i> , 2020, 40, 694-703.	3.9	32
42	Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. <i>PLoS ONE</i> , 2020, 15, e0228501.	2.5	5
43	Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 569-577.	0.9	0
44	Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. <i>United European Gastroenterology Journal</i> , 2019, 7, 838-849.	3.8	23
45	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
46	SAT-067-Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e656-e657.	3.7	0
47	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 714-726.	3.9	49
48	FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study. <i>Journal of Hepatology</i> , 2019, 70, e606-e607.	3.7	0
49	Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1226-1234.	0.9	22
50	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. <i>Liver International</i> , 2019, 39, 1307-1314.	3.9	20
51	PS-138-PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort. <i>Journal of Hepatology</i> , 2019, 70, e88-e89.	3.7	0
52	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	3.7	106
53	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 387-402.	7.7	18
54	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55.	2.6	24

#	ARTICLE	IF	CITATIONS
55	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 253-259.	2.5	44
56	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. <i>Liver International</i> , 2019, 39, 324-331.	3.9	55
57	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. <i>International Journal of Cancer</i> , 2019, 144, 2782-2794.	5.1	19
58	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 238-246.	3.8	17
59	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , 2018, 36, 78-88.	1.9	7
60	Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort. <i>BMC Cancer</i> , 2018, 18, 774.	2.6	9
61	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 489.	2.6	16
62	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. <i>European Journal of Internal Medicine</i> , 2018, 55, 57-65.	2.2	6
63	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. <i>Gastric Cancer</i> , 2017, 20, 358-367.	5.3	4
64	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1017-1025.	2.0	17
65	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	3.8	49
66	Risk estimation for biliary tract cancer: Development and validation of a prognostic score. <i>Liver International</i> , 2017, 37, 1852-1860.	3.9	21
67	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 94-102.	0.5	34
68	CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3330-3337.	1.6	215
69	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. <i>Oncotarget</i> , 2017, 8, 48688-48700.	1.8	15
70	Portal vein infiltration in patients with hepatocellular carcinoma: The relevance of correct classification.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15651-e15651.	1.6	0
71	Stagewise pseudo-value regression for time-varying effects on the cumulative incidence. <i>Statistics in Medicine</i> , 2016, 35, 1144-1158.	1.6	3
72	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	4.4	217

#	ARTICLE	IF	CITATIONS
73	Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer, 2016, 16, 758.	2.6	10
74	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer, 2016, 16, 94.	2.6	37
75	Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.. Journal of Clinical Oncology, 2016, 34, e15593-e15593.	1.6	0
76	Predictive Scores in Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2015, 49, 438-447.	2.2	12
77	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer, 2015, 15, 210.	2.6	87
78	Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer, 2015, 15, 465.	2.6	105
79	Survival analysis of proposed <scp>BCLC</scp>â€B subgroups in hepatocellular carcinoma patients. Liver International, 2015, 35, 591-600.	3.9	60
80	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	2.5	10
81	Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2015, 38, 352-360.	2.0	95
82	Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. Journal of Hepatology, 2015, 62, 863-870.	3.7	63
83	Colony-Stimulating Factor-1. Journal of the American Society of Nephrology: JASN, 2015, 26, 379-389.	6.1	45
84	CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeksâ€”A prospective randomized phase III study.. Journal of Clinical Oncology, 2015, 33, 4007-4007.	1.6	35
85	A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaÃ”ve advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2015, 33, 140-140.	1.6	0
86	Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. Journal of Experimental and Clinical Cancer Research, 2014, 33, 83.	8.6	13
87	CellMiner<scp>HCC</scp>: a microarrayâ€”based expression database for hepatocellular carcinoma cell lines. Liver International, 2014, 34, 621-631.	3.9	15
88	Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009. Journal of Clinical Gastroenterology, 2014, 48, 279-289.	2.2	80
89	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. International Journal of Clinical Oncology, 2014, 19, 288-296.	2.2	11
90	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials, 2014, 15, 311.	1.6	24

#	ARTICLE	IF	CITATIONS
91	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014, 46, 67-71.	0.9	9
92	How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?. <i>Journal of Hepatology</i> , 2013, 59, 279-284.	3.7	100
93	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Digestive and Liver Disease</i> , 2013, 45, 408-413.	0.9	31
94	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <i>Transplant International</i> , 2013, 26, 67-74.	1.6	58
95	Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. <i>Hepatology</i> , 2013, 57, 2358-2368.	7.3	141
96	Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 718-728.	1.5	38
97	Clinicopathologic Features and Prognosis of Young Patients With Hepatocellular Carcinoma in a Large German Cohort. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 775-778.	2.2	16
98	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2012, 54, 93-95.	3.1	53
99	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. <i>Digestive and Liver Disease</i> , 2012, 44, 432-437.	0.9	54
100	Midterm follow-up after DC-BEADâ„¢,â„¢-TACE of Hepatocellular Carcinoma (HCC). <i>European Journal of Radiology</i> , 2012, 81, 3857-3861.	2.6	13
101	AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature. <i>Onkologie</i> , 2011, 34, 538-542.	0.8	4
102	Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 208-213.	2.2	181
103	Library of molecular associations: curating the complex molecular basis of liver diseases. <i>BMC Genomics</i> , 2010, 11, 189.	2.8	13
104	Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment. <i>Oncology</i> , 2010, 79, 85-92.	1.9	35
105	Systemic Therapies in Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2009, 27, 175-188.	1.9	58
106	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 489-495.	2.2	146
107	Hepatocellular carcinoma in patients with autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 578.	3.3	64
108	Genome-wide analysis of factors regulating gene expression in liver. <i>Gene</i> , 2007, 389, 114-121.	2.2	6

#	ARTICLE	IF	CITATIONS
109	Genetics of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 2271.	3.3	116
110	Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 5513.	3.3	23
111	Das Interdisziplinäre Hepatologische Zentrum Mainz. <i>Visceral Medicine</i> , 2006, 22, 219-223.	1.3	1
112	Actin binding LIM protein 3 (abLIM3). <i>International Journal of Molecular Medicine</i> , 2006, 17, 129.	4.0	10
113	Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. <i>BMC Cancer</i> , 2006, 6, 232.	2.6	92
114	Current bioinformatics tools in genomic biomedical research (Review). <i>International Journal of Molecular Medicine</i> , 2006, 17, 967.	4.0	12
115	In silico characterization of LZTS3, a potential tumor suppressor. <i>Oncology Reports</i> , 2005, 14, 547.	2.6	5
116	Characterization of OEFT, a LIM protein. <i>International Journal of Molecular Medicine</i> , 2005, 15, 513.	4.0	1
117	In silico characterization of an Iroquois family-related homeodomain protein. <i>International Journal of Molecular Medicine</i> , 2005, 16, 443.	4.0	0
118	LASS6, an additional member of the longevity assurance gene family. <i>International Journal of Molecular Medicine</i> , 2005, 16, 905.	4.0	5
119	In silico characterization of an Iroquois family-related homeodomain protein. <i>International Journal of Molecular Medicine</i> , 2005, 16, 443-8.	4.0	1
120	LASS6, an additional member of the longevity assurance gene family. <i>International Journal of Molecular Medicine</i> , 2005, 16, 905-10.	4.0	14
121	Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. <i>Biochemical Pharmacology</i> , 1999, 58, 1381-1387.	4.4	30
122	TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis. <i>Human Immunology</i> , 1996, 51, 49-54.	2.4	37